Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Curr Oncol. 2023 May 26;30(6):5322-5336. doi: 10.3390/curroncol30060404.
This review aims to describe the systemic treatment options for pancreatic ductal adenocarcinoma and includes a summary of the current treatments as well as the ongoing clinical trials which may be efficacious in the treatment of this aggressive malignancy.
A literature review was performed using MEDLINE/PubMed between August 1996 and February 2023. The reviewed studies are categorized into these categories: current standard of care treatments, targeted therapies, immunotherapy and clinical trials. The current treatment modality for the treatment of advanced pancreatic cancer is mainly systemic chemotherapy.
The introduction of polychemotherapy regimens including gemcitabine/nab-paclitaxel and FOLFIRINOX (oxaliplatin, irinotecan, folinic acid and fluorouracil) has improved the clinical outcome of advanced pancreatic cancer. For further improvement in clinical outcomes, several novel approaches have been extensively studied in pancreatic cancer. The review discusses the current standard chemotherapy regimen and the novel treatment options in the field.
While there are novel treatments being explored for metastatic pancreatic, it remains a debilitating and aggressive disease with high mortality that warrants continued efforts to advance therapeutic options.
本综述旨在描述胰腺导管腺癌的系统治疗选择，包括对当前治疗方法的总结以及正在进行的临床试验，这些临床试验可能对治疗这种侵袭性恶性肿瘤有效。
使用 MEDLINE/PubMed 在 1996 年 8 月至 2023 年 2 月期间进行了文献回顾。所回顾的研究分为以下几类：当前的标准治疗方法、靶向治疗、免疫疗法和临床试验。目前治疗晚期胰腺癌的主要方法是系统化疗。
包括吉西他滨/白蛋白结合型紫杉醇和 FOLFIRINOX（奥沙利铂、伊立替康、亚叶酸钙和氟尿嘧啶）在内的多化疗方案的引入改善了晚期胰腺癌的临床结果。为了进一步改善临床结果，在胰腺癌领域已经广泛研究了几种新的方法。本文综述了当前的标准化疗方案和新的治疗选择。
尽管正在探索转移性胰腺的新疗法，但它仍然是一种使人衰弱且侵袭性的疾病，死亡率很高，需要继续努力推进治疗选择。
